Article

Jetrea launches in Canada

Alcon Laboratories Inc. has launched ocriplasmin, its treatment of symptomatic vitreomacular adhesion (VMA), in Canada.

 

Leuven, Belgium-Alcon Laboratories Inc. has launched ocriplasmin, its treatment of symptomatic vitreomacular adhesion (VMA), in Canada.

Canada is the first market where ocriplasmin (Jetrea) has been launched outside the United States and Europe.

Health Canada approved the treatment in August following priority review.

Alcon, a division of Novartis, acquired the rights to commercialize the treatment outside the United States in March 2012. It launched the drug in the United Kingdom-its first European market-in April, and was then followed by launches in Germany, Denmark, Findlay, Norway, and Sweden.

ThromboGenics NV is commercializing the drug in the United States, having launched it in January.

“The launch of (ocriplasmin) in Canada . . . is another important step in the global roll out of this innovative new drug for the treatment of symptomatic VMA,” said Patrik De Haes, MD, chief executive officer of ThromboGenics. “We are looking forward to working with Alcon as it continues to roll out (the treatment).”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
© 2025 MJH Life Sciences

All rights reserved.